Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus AI Neoadjuvant Therapy for HR+/HER2- Breast Cancer
NCT06613373Phase 4Not yet recruiting
- Sponsor
- Jiangsu Famous Medical Technology
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of dalpiciclib in breast cancer, sponsored by Jiangsu Famous Medical Technology. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06613373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613373.